Edwards Lifesciences' transcatheter aortic valve implantation system proves effective in the 1st reports from a global registry of valve-in-valve TAVI patients, but safety issues raise eyebrows.
Updated October 3, 2012, at 9:45 p.m. to correct the lead story.
MASSDEVICE ON CALL — The 1st reports from a global registry evaluating Edwards Lifesciences' (NYSE:EW) Sapien transcatheter aortic valve implantation inside a failing valve or mitral ring came with mixed results.*
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
If you read nothing else today, make sure you're still in the know with MassDevice +3.